MMMinerva Neurosciences Inc
2.26EURR
−0.10−4.24%
As of today at 19:13 GMT
EUR
No trades
4MNA fundamentals
Key facts
Market capitalization17.02 MEUR
Basic EPS (TTM)1.26EUR
Founded2007
CEORémy Henri Luthringer
Websiteminervaneurosciences.com
About
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
−8.00 M
0.00
8.00 M
16.00 M
24.00 M
Revenue
Net income
Net margin %
Estimates
Revenue and Earnings forecasts and estimates accuracy
Dividends
Dividend yield, history and sustainability
No dividends
4MNA has never paid dividends and has no current plans to do so.
Financial health
Financial position and solvency of the company